MK-1045 / Merck (MSD) - LARVOL DELTA

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: MSD R&D (China) Co., Ltd. | Trial completion date: Dec 2025 ➔ Sep 2027 | Trial primary completion date: Jun 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CN201-103: A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) (clinicaltrials.gov) - P1/2 | N=203 | Recruiting | Sponsor: MSD R&D (China) Co., Ltd. | Trial completion date: Jul 2025 ➔ Jan 2027 | Trial primary completion date: May 2025 ➔ Jan 2027

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (Businesswire) - "Merck...announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases."

Commercial • B Acute Lymphoblastic Leukemia • Non-Hodgkin’s Lymphoma

Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (Merck (MSD) Press Release) - "Merck...and Curon Biopharmaceutical...announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases....Under the terms of the agreement, Merck through a subsidiary will acquire full global rights to CN201 for an upfront payment of $700 million in cash. Curon is also eligible to receive up to $600 million in milestone payments associated with the development and regulatory approval of CN201....The transaction is expected to close in the third quarter of 2024 and be accounted for as an asset acquisition."

Commercial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. (ASCO 2024) - P1 | "CN201 has a well tolerable safety profile and promising anti-tumor activity in patients with R/R B-NHL."

Clinical • P1 data • Anemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. (ASCO 2024) - P1/2 | "Preliminary data show CN201 has a well tolerable safety profile and promising activity in adult patients with relapsed or refractory ALL."

Clinical • P1 data • Acute Lymphocytic Leukemia • Anemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Leukemia • Leukopenia • Neutropenia • Oncology • Thrombocytopenia

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201 (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Curon Biopharmaceutical (Shanghai) Co.,Ltd

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=203 | Recruiting | Sponsor: Curon Biopharmaceutical (Shanghai) Co.,Ltd | N=113 ➔ 203 | Trial completion date: Dec 2024 ➔ Jul 2025 | Trial primary completion date: Feb 2024 ➔ May 2025

Enrollment change • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

An Open-label, Multi-center Phase Ib/II Study of CN201 in Adult Subjects With Precursor B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=113 | Recruiting | Sponsor: Curon Biopharmaceutical (Shanghai) Co.,Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

An Open-label, Multi-center Phase Ib/II Study of CN201 in Adult Subjects With Precursor B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=113 | Not yet recruiting | Sponsor: Curon Biopharmaceutical (Shanghai) Co.,Ltd

New P1/2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology